Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pentolinium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BBOX1 | O75936 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 4/20 | 0.53 |
| ▸ | APOBEC3A | P31941 | 2/20 | 0.53 |
| ▸ | APOBEC3G | Q9HC16 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.39 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.39 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3674134 | 1.00 | BBOX1 (0.56) | BBOX1LMNAAPOBEC3AAPOBEC3GKMT2A | |
| SCHEMBL2393255 | 1.00 | BBOX1 (0.56) | BBOX1LMNAAPOBEC3AAPOBEC3GKMT2A | |
| SCHEMBL2158184 | 1.00 | BBOX1 (0.56) | BBOX1LMNAAPOBEC3AAPOBEC3GKMT2A | |
| SCHEMBL7593954 | 1.00 | BBOX1 (0.56) | BBOX1LMNAAPOBEC3AAPOBEC3GKMT2A | |
| SCHEMBL12638424 | 1.00 | BBOX1 (0.56) | BBOX1LMNAAPOBEC3AAPOBEC3GKMT2A | |
| SCHEMBL3043744 | 0.97 | LMNA (0.57) | BBOX1LMNAAPOBEC3AAPOBEC3GKMT2A | |
| SCHEMBL3037609 | 0.97 | LMNA (0.57) | BBOX1LMNAAPOBEC3AAPOBEC3GKMT2A | |
| SCHEMBL923466 | 0.97 | LMNA (0.57) | BBOX1LMNAAPOBEC3AAPOBEC3GKMT2A | |
| Bromide SCHEMBL7605138 | 0.97 | BBOX1 (0.54) | BBOX1LMNAAPOBEC3AAPOBEC3GKMT2A | |
| Water SCHEMBL29283573 | 0.97 | BBOX1 (0.54) | BBOX1LMNAAPOBEC3AAPOBEC3GKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1186 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12605345-B2 | Transdermal drug delivery system | BioPhysics Pharma, Inc. (US) | 2026-04-21 | — | — | US | claimed |
| US-20250268841-A1 | Trans-Epithelial Membrane Drug Delivery System | Masiz, John J. (US) | 2025-08-28 | — | — | US | claimed |
| US-20250120907-A1 | Transmucosal Drug Delivery System | Masiz, John J. (US) | 2025-04-17 | — | — | US | claimed |
| US-12246098-B2 | Trans-epithelial membrane drug delivery system | BioPhysics Pharma, Inc. (US) | 2025-03-11 | — | — | US | claimed |
| US-20240216292-A1 | Trans-Epithelial Membrane Drug Delivery System | Masiz, John J. (US) | 2024-07-04 | — | — | US | claimed |
| US-20240108588-A1 | Transdermal Drug Delivery System | Masiz, John J. (US) | 2024-04-04 | — | — | US | claimed |
| US-11865217-B2 | Transdermal drug delivery system | BioPhysics Pharma, Inc. (US) | 2024-01-09 | — | — | US | claimed |
| EP-4106816-A1 | TRANSMUCOSAL DRUG DELIVERY SYSTEM | North Atlantic Holdings LLC (US) | 2022-12-28 | — | — | EP | claimed |
| US-20220387343-A1 | Transdermal Drug Delivery System | Masiz, John J. (US) | 2022-12-08 | — | — | US | claimed |
| US-11446257-B2 | Transdermal drug delivery system | BioPhysics Pharma, Inc. (US) | 2022-09-20 | — | — | US | claimed |
| US-5686448-A | Treatment of virus infections with ganglionic blocking agents | BALTECH, INC. (US) | 1997-11-11 | — | — | US | claimed |
| US-5554610-A | Inhalational treatment of pulmonary hypertension and related conditions | BEECHAM GROUP P.L.C. (GB) | 1996-09-10 | — | — | US | claimed |
| WO-1996001050-A1 | PREVENTION AND TREATMENT OF HUMAN HERPESVIRUS-6 INFECTION WITH QUATERNARY AMMONIUM COMPOUNDS AND/OR GANGLIONIC BLOCKING AGENTS | BALTECH, INC. (US) | 1996-01-18 | — | — | WO | claimed |
| EP-0333769-A4 | COMBINATIONS OF RENAL VASODILATORS AND ALPHA 1-ADRENERGIC OR GANGLIONIC BLOCKING AGENTS FOR TREATING DISEASES. | NEW YORK MEDICAL COLLEGE (US) | 1990-06-27 | — | — | EP | claimed |
| US-4902720-A | Treatment of virus infections with quaternary ammonium compounds | BALTECH, INC., A CORP. OF LA | 1990-02-20 | — | — | US | claimed |
| US-4898888-A | SUCH AS TETRAETHYLAMMONIUM OR HEXAMETHONIUM ION; HERPES SIMPLEX | BALTECH, INC. | 1990-02-06 | — | — | US | claimed |
| EP-0333769-A1 | COMBINATIONS OF RENAL VASODILATORS AND ALPHA 1-ADRENERGIC OR GANGLIONIC BLOCKING AGENTS FOR TREATING DISEASES | NEW YORK MEDICAL COLLEGE (US) | 1989-09-27 | — | — | EP | claimed |
| WO-1988004179-A1 | COMBINATIONS OF RENAL VASODILATORS AND alpha1-ADRENERGIC OR GANGLIONIC BLOCKING AGENTS AND METHODS FOR TREATING DISEASES | NEW YORK MEDICAL COLLEGE (US) | 1988-06-16 | — | — | WO | claimed |
| US-4749686-A | Combinations of renal vasodilators and α1 -adrenergic or ganglionic blocking agents and methods for treating diseases | NEW YORK MEDICAL COLLEGE (US) | 1988-06-07 | — | — | US | claimed |
| US-4721707-A | ALKALI METAL NITROPRUSSIDE AND TRIMETHAPAN SALT | CIERPKA HENNING (CH) | 1988-01-26 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12605345-B2 | Transdermal drug delivery system | FABP2, VEGFA, CUTA | BBOX1 3839/4885LMNA 512/4885APOBEC3A 4317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.